Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBT Margin (2016 - 2025)

Haemonetics (HAE) has 17 years of EBT Margin data on record, last reported at 17.69% in Q4 2025.

  • For Q4 2025, EBT Margin rose 337.0% year-over-year to 17.69%; the TTM value through Dec 2025 reached 17.23%, up 524.0%, while the annual FY2025 figure was 15.58%, 398.0% up from the prior year.
  • EBT Margin reached 17.69% in Q4 2025 per HAE's latest filing, up from 15.67% in the prior quarter.
  • Across five years, EBT Margin topped out at 21.4% in Q1 2025 and bottomed at 12.17% in Q2 2021.
  • Average EBT Margin over 5 years is 10.88%, with a median of 13.02% recorded in 2023.
  • Peak YoY movement for EBT Margin: tumbled -2138bps in 2021, then skyrocketed 1796bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 8.3% in 2021, then surged by 67bps to 13.83% in 2022, then fell by -5bps to 13.09% in 2023, then increased by 9bps to 14.32% in 2024, then rose by 24bps to 17.69% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 17.69% in Q4 2025, 15.67% in Q3 2025, and 14.05% in Q2 2025.